Amgen Inc. (AMGN)
| Market Cap | 153.76B |
| Revenue (ttm) | 33.42B |
| Net Income (ttm) | 4.09B |
| Shares Out | 537.65M |
| EPS (ttm) | 7.56 |
| PE Ratio | 37.83 |
| Forward PE | 13.87 |
| Dividend | $11.51 (4.03%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 3,447,705 |
| Open | 283.13 |
| Previous Close | 281.41 |
| Day's Range | 277.13 - 287.90 |
| 52-Week Range | 253.30 - 346.85 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 324.68 (+13.53%) |
| Earnings Date | May 1, 2025 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is $324.68, which is an increase of 13.53% from the latest price.
News
Switzerland's Sandoz files antitrust lawsuit against Amgen in US
Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for entrenching the dominant market position of its blockbuster medicine, Enbrel (etan...
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif. , April 11, 2025 /PRNew...
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squ...
Global pharma shares plunge as Trump doubles down on tariff threat
Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and...
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo UPLIZNA Shown to Deliver Corticosteroid-Free, Flare-Free, Complete Remission for Patients in...
US FDA approves expanded use of Amgen's rare disease drug
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said ...
Final Trades: Amgen, Sabra Health Care and Kinsale Capital Group
Final Trades: Amgen, Sabra Health Care and Kinsale Capital Group.
Dogs Of The Dow Chase April's 'Safer' Buy
Verizon is the only Dow Dog currently meeting the ideal of annual dividends from $1K invested exceeding its single share price. Analysts forecast net gains of 13.06% to 37.60% for the top-ten Dow Dogs...
Amgen: Excellent Buy And Hold For A Volatile Market
Amgen is a robust long-term investment due to its strong profitability, competitive moat, and promising pipeline, including an anti-obesity drug. Despite modest short-term growth guidance, AMGN's Hori...
Trade Tracker: Kevin Simpson buys Howmet, buys more Amgen
Kevin Simpson, Capital Wealth Planning founder and CIO, joins CNBC's "Halftime Report" to detail his latest portfolio buys.
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Trade Tracker: Karen Firestone buys Amgen and buys more HealthEquity
Karen Firestone, executive chairman at Aureus Asset Management, joins CNBC's "Halftime Report" to detail her latest stock purchases. The Investment Committee debate healthcare and biotech companies.
Widely used drugs on US imports list from Europe
Widely used prescription medicines could get caught up in the Trump administration's tariff trade wars and EU retaliation.
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
Patients Reported Improvement in Ability to Conduct Daily Activities with Twice-Yearly Dosing * Late-Breaking Data to be Presented at AAN 2025 THOUSAND OAKS, Calif. , March 13, 2025 /PRNewswire/ -- Am...
Amgen: Riding The MariTide Of Monthly Weight Loss
Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual mechanism a...